Abstract |
Nasal-type, extranodal NK/T cell lymphoma (ENKTCL) is a special type of lymphomas with geographic and racial specificity. Up to now, the standard first-line treatment is still not unified. In our previous report, the "sandwich" protocol produced good results. Continuing to use the "sandwich" mode, a new chemotherapy composed of L- asparaginase, cisplatin, etoposide and dexamethasone (LVDP) plus concurrent chemoradiotherapy (CCRT) was conducted in more patients with newly diagnosed, I/II stage ENKTCL. The results showed that 66 patients were enrolled. Overall response rate was 86.4% including 83.3% complete response and 3.0% partial remission. With the median follow-up of 23.5 months, 3-year overall survival and 3-year progression-free survival were 70.1% and 67.4%, respectively. The survival rate in stage II and extra-cavity stage I was significantly less than that in limited stage I (p < 0.05). Therefore, we thought that the "sandwich" mode was worthy of being generalized and LVDP combined with CCRT was an effective protocol for I/II stage ENKTCL. But this regimen was not suitable for all stage I/II patients and warrants larger sample and layering investigation. This study was a registered clinical trial with number ChiCTR-TNC-12002353.
|
Authors | Ming Jiang, Li Zhang, Li Xie, Hong Zhang, Yu Jiang, Wei-Ping Liu, Wen-Yan Zhang, Rong Tian, Yao-Tiao Deng, Sha Zhao, Li-Qun Zou |
Journal | Oncotarget
(Oncotarget)
Vol. 8
Issue 30
Pg. 50155-50163
(Jul 25 2017)
ISSN: 1949-2553 [Electronic] United States |
PMID | 28404973
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Etoposide
- Dexamethasone
- Asparaginase
- Cisplatin
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology, therapeutic use)
- Asparaginase
(pharmacology, therapeutic use)
- Chemoradiotherapy
(methods)
- Cisplatin
(pharmacology, therapeutic use)
- Dexamethasone
(pharmacology, therapeutic use)
- Etoposide
(pharmacology, therapeutic use)
- Female
- Humans
- Lymphoma, Extranodal NK-T-Cell
(drug therapy, mortality, pathology, radiotherapy)
- Male
- Middle Aged
- Neoplasm Staging
- Prospective Studies
- Survival Analysis
- Treatment Outcome
- Young Adult
|